Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18720922 | 0.91 | LMNA (0.48) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL23867079 | 0.89 | LMNA (0.62) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL8736714 | 0.89 | MEN1 (0.39) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL5605601 | 0.88 | LMNA (0.46) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL4579218 | 0.88 | LMNA (0.46) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL7864089 | 0.88 | LMNA (0.46) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL23522266 | 0.88 | LMNA (0.46) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL23522267 | 0.88 | LMNA (0.46) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL30979277 | 0.88 | LMNA (0.46) | MEN1CYP3A4ALOX15KMT2ALMNA | |
| SCHEMBL28071928 | 0.88 | LMNA (0.46) | MEN1CYP3A4ALOX15KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062631-A1 | CYCLOOCTANE CONTAINING FUEL COMPOSITIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2026-03-05 | — | — | US | claimed |
| US-20240400784-A1 | Method for Screening Solvent for Extracting Polyvinyl Chloride, Method for Recycling Waste, Recycled Polyvinyl Chloride, and Composition | LG CHEM, LTD. (KR) | 2024-12-05 | — | — | US | claimed |
| US-20240392094-A1 | Method for Screening Solvent for Polyvinyl Chloride Extraction, Recycling Method for Waste Material, and Recycled Polyvinyl Chloride and Composition | LG CHEM, LTD. (KR) | 2024-11-28 | — | — | US | claimed |
| WO-2023033601-A1 | METHOD FOR SCREENING SOLVENT FOR POLYVINYL CHLORIDE EXTRACTION, RECYCLING METHOD FOR WASTE MATERIAL, AND RECYCLED POLYVINYL CHLORIDE AND COMPOSITION | 주식회사 엘지화학 | 2023-03-09 | — | — | WO | claimed |
| WO-2023033605-A1 | METHOD FOR SCREENING SOLVENT FOR EXTRACTING POLYVINYL CHLORIDE, METHOD FOR RECYCLING WASTE, RECYCLED POLYVINYL CHLORIDE, AND COMPOSITION | 주식회사 엘지화학 | 2023-03-09 | — | — | WO | claimed |
| EP-2829555-B1 | METHOD FOR PRODUCING OLEFIN POLYMER | MITSUI CHEMICALS INC (JP) | 2018-05-16 | — | — | EP | claimed |
| CN-104203993-B | Process for producing olefin polymer | 三井化学株式会社 | 2016-06-15 | — | — | CN | claimed |
| US-9315602-B2 | Method for producing olefin polymer | MITSUI CHEMICALS, INC. (JP) | 2016-04-19 | — | — | US | claimed |
| US-7105685-B2 | Viricides treating Human Immunodeficiency Viruses; antitumor agents | TRAVIS CRAIG R | 2006-09-12 | — | — | US | claimed |
| US-20040242870-A1 | Cannbichromene derivative; aids therapy | IMMUGEN PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | claimed |
| US-20030158191-A1 | Cannabinol derivatives | TRAVIS CRAIG R (US) | 2003-08-21 | — | — | US | claimed |
| US-6541510-B2 | Cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus, especially HIV. | IMMUGEN PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | claimed |
| JP-2002539246-A | — | — | 2002-11-19 | — | — | JP | claimed |
| CN-1377261-A | Treating immune diseases | IMMUNGEN PHARMACEUTICALS INC (US) | 2002-10-30 | — | — | CN | claimed |
| US-20020068738-A1 | Antiviral methods and compounds | IMMUGEN PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | claimed |
| WO-2002026728-A2 | ANTIVIRAL METHODS AND COMPOUNDS | IMMUGEN PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| EP-1189603-A2 | TREATMENT OF IMMUNE DISEASES LIKE HIV DISEASE AND NEOPLASTIC DISORDERS | Immugen Pharmaceuticals, Inc. (US) | 2002-03-27 | — | — | EP | claimed |
| US-6274635-B1 | ANTITUMOR AGENTS | IMMUGEN PHARMACEUTICALS INC. | 2001-08-14 | — | — | US | claimed |
| WO-2000056303-A2 | TREATMENT OF IMMUNE DISEASES | IMMUGEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | claimed |
| EP-0056938-B1 | PROCESS FOR THE PREPARATION OF 3,6-DISUBSTITUTED 4-AMINO-1,2,4-TRIAZIN-5-ONES | BAYER AG (DE) | 1985-03-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158191-A1 | Cannabinol derivatives | CNR2, CNR1, GPR18 | MEN1 2048/4885CYP3A4 103/4885ALOX15 906/4885 |
| US-20020068738-A1 | Antiviral methods and compounds | MAVS, CNR1, ZC3HAV1 | MEN1 3675/4885CYP3A4 2052/4885ALOX15 403/4885 |
| US-20040242870-A1 | Cannbichromene derivative; aids therapy | CNR1, CNR2, MKI67 | MEN1 2365/4885CYP3A4 1707/4885ALOX15 118/4885 |
| US-20260062631-A1 | CYCLOOCTANE CONTAINING FUEL COMPOSITIONS | CPT1A, CPT2, CNR2 | MEN1 3703/4885CYP3A4 403/4885ALOX15 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.